- Home
- ORGO vs BOE Comparison
ORGO vs BOE Comparison
Compare ORGO & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- BOE
- Stock Information
- Founded
- ORGO 1985
- BOE 2005
- Country
- ORGO United States
- BOE United States
- Employees
- ORGO N/A
- BOE N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- BOE Trusts Except Educational Religious and Charitable
- Sector
- ORGO Health Care
- BOE Finance
- Exchange
- ORGO Nasdaq
- BOE Nasdaq
- Market Cap
- ORGO 533.9M
- BOE 634.0M
- IPO Year
- ORGO N/A
- BOE N/A
- Fundamental
- Price
- ORGO $5.34
- BOE $10.92
- Analyst Decision
- ORGO Buy
- BOE
- Analyst Count
- ORGO 2
- BOE 0
- Target Price
- ORGO $5.50
- BOE N/A
- AVG Volume (30 Days)
- ORGO 1.7M
- BOE 166.1K
- Earning Date
- ORGO 05-08-2025
- BOE 01-01-0001
- Dividend Yield
- ORGO N/A
- BOE 7.30%
- EPS Growth
- ORGO N/A
- BOE N/A
- EPS
- ORGO N/A
- BOE N/A
- Revenue
- ORGO $482,043,000.00
- BOE N/A
- Revenue This Year
- ORGO $3.31
- BOE N/A
- Revenue Next Year
- ORGO $12.50
- BOE N/A
- P/E Ratio
- ORGO N/A
- BOE N/A
- Revenue Growth
- ORGO 11.29
- BOE N/A
- 52 Week Low
- ORGO $2.17
- BOE $8.80
- 52 Week High
- ORGO $6.71
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- ORGO 67.16
- BOE 58.24
- Support Level
- ORGO $5.14
- BOE $10.76
- Resistance Level
- ORGO $5.42
- BOE $10.78
- Average True Range (ATR)
- ORGO 0.28
- BOE 0.15
- MACD
- ORGO 0.09
- BOE 0.07
- Stochastic Oscillator
- ORGO 85.09
- BOE 94.17
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.